Long-term carvedilol therapy effects on left ventricular remodeling and glycemia in patients with chronic heart failure and Type 2 diabetes mellitus

• Main Authors: R. R. Samedov, A. B. Bakhshaliev
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 2008-02-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: type 2 diabetes mellitus; chronic heart failure; beta-adrenoblockers; carvedilol
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/1062
• ISSN: 1728-8800; 2619-0125

Aim. To study the effects of long6term carvedilol treatment on left ventricular (LV) remodeling and glycemia control parameters in patients with chronic heart failure (CHF) due to post6infarction cardiosclerosis, and Type 2 diabetes mellitus (DM-2).Material and methods. This 12-month study included 30 patients with functional Class (FC) II-III CHF by NYHA classification, LV ejection fraction (EF) <40% and DM-2. Carvedilol was administered in the daily dose of 6,25-25 mg.Results. Carvedilol therapy was associated with substantial heart rate reduction: from 103,5±4,6 to 79,7±2,3 bpm (р<0,001). After 12 months, end-diastolic and end-systolic volumes decreased from 199,4±32,7 to 182,7±36,8and from 132,0±27,9 to 112,8±31,3 ml, respectively (р<0,001), LV EF increased from 34,22±3,80 to 39,04±5,39%. Carvedilol therapy did not affect glycemia levels: 178,0±12,97 mg/dl at baseline, 180,27±12,72 mg/dl in the end of the study (р>0,05).Conclusion. Long-term carvedilol therapy was associated with improved clinic and hemodynamic status, as well as delayed LV remodeling, without affecting glycemia levels in patients with CHF and DM-2.